According to the firm, the Rs 120 crores ($1.6m) investment will enhance Sun Pharma’s capacity to manufacture lyophilized vials, liquid ampoules, and eye drops at the 14-acre Guwahati site.
Located in India’s eastern state of Assam, the Guwahati facility also houses granulation, tablet compression, and capsule filling capabilities.
Sun Pharma’s managing director, Dilip Shanghvi, said this latest investment responds to a governmental push for increased industrial activities and employment opportunities in Assam.
“Sun Pharma is committed to the government’s ‘Make in India’ initiative,” Shanghvi told delegates at the production line launch.
“In the next few years, the Guwahati plant is expected to become of the largest facilities in our network to manufacture sterile products,” he added.
In August, the firm launched its extended-release Kapspargo Sprinkle drug product for the treatment of hypertension, angina pectoris or heart failure.
The following month, Sun Pharma announced its eye disease treatment, Cequa (cyclosporine ophthalmic solution) had received US Food and Drug Administration approval.